| Business Summary | | Trinity
Medical
Group
USA,
Inc.,
an
affiliate
of
Trinity
Medical
Group,
Ltd.,
a
Thailand
company,
is
a
late
development
stage
company
with
rights
to
market
an
HIV-Immunogen
known
as
REMUNE,
a
patented
therapeutic
vaccine
treatment,
designed
to
induce
specific
T
cell
responses
in
people
infected
with
the
Human
Immunodeficiency
Virus
(HIV).
REMUNE
is
an
immune-based
therapy
consisting
of
whole,
inactivated
HIV-1
virus
depleted
of
its
gp120
coat
protein
based
on
Dr.
Jonas
Salk's
vaccine
technology. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Trinity
Medical
Group
is
a
late
development
stage
company
with
rights
to
market
a
patented
therapeutic
vaccine
known
as
REMUNE,
which
is
designed
to
induce
specific
T
cell
responses
in
people
infected
with
the
Human
Immunodeficiency
Virus
(HIV).
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenue.
Net
loss
totaled
$2.1
million,
up
from
$449
thousand.
Results
reflect
higher
research
and
development
expenses
and
an
increase
in
SG&A
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Arun Churdboonchart, 59 Chairman | -- | James Namnath, 44 CEO,
Director | $268K | Vina Churdboonchart, 55 Pres,
Director | -- | Gary Wilson, 34 CFO,
Exec. VP-Fin., Treasurer | 194K | Elizabeth Namnath, 49 Sec. | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|